Progenics Pharma (PGNX) – Business Wire
-
Lantheus Completes Merger with Progenics
-
Lantheus Stockholders Approve Share Issuance For Merger with Progenics
-
Velan Capital Agrees to Support Merger of Lantheus and Progenics
-
Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger
-
Lantheus and Progenics Agree to Amended Transaction Terms
-
Velan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics Board
-
Glass Lewis Recommends Stockholders Vote on GREEN Consent Card for Velan Nominees to Constitute Majority of Progenics Board
-
ISS Recommends Shareholders Vote on the GREEN Consent Card for Election of Velan Nominees and Removal of Progenics CEO
-
Independent Director Candidates Nominated by Velan Issue Letter to Progenics Shareholders
-
Velan Responds to Misleading Communications from Progenics
-
Velan Sends Letter to Progenics Stockholders
-
Velan Issues Presentation Outlining Nominees’ Comprehensive Strategic Plan to Save Progenics
-
Velan Sends Letter to Progenics Pharmaceuticals Stockholders and Files Definitive Consent Statement
-
Velan Comments on Announced Sale of Progenics to Lantheus
-
Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company
-
Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees
Back to PGNX Stock Lookup
